Drug Database · Clinicians

Irinotecan

Brands (34) Irican, Iritanz, Iritero…Show all

US brand (reference label): Camptosar; not a Philippine-registered brand.

Antineoplastic (cell-cycle specific agent); Antineoplastic (topoisomerase 1 (TOP1) inhibitor); and others PH FDA category

Rx · Prescription drug46 PH productsPNF-listedVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID e518dfc6-7e93-4fee-a66c-51e1ab71c056, version date May 12, 2026 (Camptosar · Pharmacia & Upjohn Company LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
  • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE

  • CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.
  • CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CAMPTOSAR is a topoisomerase inhibitor indicated for:
  • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1)
  • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (1)

Contraindications

4 CONTRAINDICATIONS • CAMPTOSAR Injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. • Hypersensitivity to CAMPTOSAR or its excipients (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Colorectal cancer combination regimen 1: CAMPTOSAR 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m 2 intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks. (2.1)
  • • Colorectal cancer combination regimen 2: CAMPTOSAR 180 mg/m 2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m 2 intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m 2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m 2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30. (2.1)
  • • Colorectal cancer single agent regimen 1: CAMPTOSAR 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (2.2)
  • • Colorectal cancer single agent regimen 2: CAMPTOSAR 350 mg/m 2 intravenous infusion over 90 minutes on day 1 every 3 weeks. (2.2)
2.1 Colorectal Cancer Combination Regimens 1 and 2

2.1 Colorectal Cancer Combination Regimens 1 and 2 Administer CAMPTOSAR as a 90-minute intravenous infusion followed by LV and 5-FU. The currently recommended regimens are shown in Table 1. A reduction in the starting dose by one dose level of CAMPTOSAR may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels.

Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients. Table 1. Combination-Agent Dosage Regimens and Dose Modifications Dose reductions beyond Dose Level –2 by decrements of ≈ 20% may be warranted for patients continuing to experience toxicity.

Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. Regimen 1 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43) CAMPTOSAR LV 5-FU 125 mg/m 2 intravenous infusion over 90 minutes, days 1,8,15,22 20 mg/m 2 intravenous injection bolus, days 1,8,15,22 500 mg/m 2 intravenous injection bolus, days 1,8,15,22 Starting Dose & Modified Dose Levels (mg/m 2) Starting Dose Dose Level -1 Dose Level -2 CAMPTOSAR 125 100 75 LV 20 20 20 5-FU 500 400 300 Regimen 2 6-wk cycle with infusional 5-FU/LV (next cycle begins on day 43) CAMPTOSAR 180 mg/m 2 intravenous infusion over 90 minutes, days 1,15,29 LV 200 mg/m 2 intravenous infusion over 2 hours, days 1,2,15,16,29,30 5-FU Bolus 400 mg/m 2 intravenous injection bolus, days 1,2,15,16,29,30 5-FU Infusion Infusion follows bolus administration. 600 mg/m 2 intravenous infusion over 22 hours, days 1,2,15,16,29,30 Starting Dose & Modified Dose Levels (mg/m 2) Starting Dose Dose Level -1 Dose Level -2 CAMPTOSAR 180 150 120 LV 200 200 200 5-FU Bolus 400 320 240 5-FU Infusion 600 480 360 Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Dose Modifications Based on recommended dose levels described in Table 1, Combination Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 2, Recommended Dose Modifications for Combination Regimens. All dose modifications should be based on the worst preceding toxicity.

Table 2. Recommended Dose Modifications for CAMPTOSAR/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination Schedules Patients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administration. A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm 3, and the platelet count has recovered to ≥100,000/mm 3, and treatment-related diarrhea is fully resolved.

Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing therapy. Toxicity NCI CTC Grade National Cancer Institute Common Toxicity Criteria (version 1.0) (Value) During a Cycle of Therapy At the Start of Subsequent Cycles of Therapy Relative to the starting dose used in the previous cycle No toxicity Maintain dose level Maintain dose level Neutropenia 1 (1500 to 1999/mm 3) Maintain dose level Maintain dose level 2 (1000 to 1499/mm 3) ↓ 1 dose level Maintain dose level 3 (500 to 999/mm 3) Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level ↓ 1 dose level 4 (<500/mm 3) Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels ↓ 2 dose levels Neutropenic fever Omit dose until resolved, then ↓ 2 dose levels Other hematologic toxicities Dose modifications for leukopenia or thrombocytopenia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

Diarrhea 1 (2–3 stools/day > pretx Pretreatment) Delay dose until resolved to baseline, then give same dose Maintain dose level 2 (4–6 stools/day > pretx) Omit dose until resolved to baseline, then ↓ 1 dose level Maintain dose level 3 (7–9 stools/day > pretx) Omit dose until resolved to baseline, then ↓ 1 dose level ↓ 1 dose level 4 (≥10 stools/day > pretx) Omit dose until resolved to baseline, then ↓ 2 dose levels ↓ 2 dose levels Other nonhematologic toxicities Excludes alopecia, anorexia, asthenia 1 Maintain dose level Maintain dose level 2 Omit dose until resolved to ≤ grade 1, then ↓ 1 dose level Maintain dose level 3 Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level ↓ 1 dose level 4 Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels ↓ 2 dose levels For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR.

2.2 Colorectal Single Agent Regimens 1 and 2

2.2 Colorectal Single Agent Regimens 1 and 2 Administer CAMPTOSAR as a 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3. A reduction in the starting dose by one dose level of CAMPTOSAR may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels.

Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients. Table 3. Single-Agent Regimens of CAMPTOSAR and Dose Modifications Regimen 1 (weekly) Subsequent doses may be adjusted as high as 150 mg/m 2 or to as low as 50 mg/m 2 in 25 to 50 mg/m 2 decrements depending upon individual patient tolerance. 125 mg/m 2 intravenous infusion over 90 minutes, days 1,8,15,22 then 2-week rest Starting Dose and Modified Dose Levels Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.

(mg/m 2) Starting Dose Dose Level -1 Dose Level -2 125 100 75 Regimen 2 (every 3 weeks) Subsequent doses may be adjusted as low as 200 mg/m 2 in 50 mg/m 2 decrements depending upon individual patient tolerance. 350 mg/m 2 intravenous infusion over 90 minutes, once every 3 weeks Starting Dose and Modified Dose Levels (mg/m 2) Starting Dose Dose Level -1 Dose Level -2 350 300 250 Dose Modifications Based on recommended dose-levels described in Table 3, Single-Agent Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.

Table 4. Recommended Dose Modifications For Single-Agent Schedules All dose modifications should be based on the worst preceding toxicity A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm 3, and the platelet count has recovered to ≥100,000/mm 3, and treatment-related diarrhea is fully resolved.

Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing CAMPTOSAR. Worst Toxicity NCI Grade National Cancer Institute Common Toxicity Criteria (version 1.0) (Value) During a Cycle of Therapy At the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with the Starting Dose in the Previous Cycle Weekly Weekly Once Every 3 Weeks No toxicity Maintain dose level ↑ 25 mg/m 2 up to a maximum dose of 150 mg/m 2 Maintain dose level Neutropenia 1 (1500 to 1999/mm 3) Maintain dose level Maintain dose level Maintain dose level 2 (1000 to 1499/mm 3) ↓ 25 mg/m 2 Maintain dose level Maintain dose level 3 (500 to 999/mm 3) Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 (<500/mm 3) Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2 Neutropenic fever Omit dose until resolved, then ↓ 50 mg/m 2 when resolved ↓ 50 mg/m 2 ↓ 50 mg/m 2 Other hematologic toxicities Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

Diarrhea 1 (2–3 stools/day > pretx Pretreatment) Maintain dose level Maintain dose level Maintain dose level 2 (4–6 stools/day > pretx) ↓ 25 mg/m 2 Maintain dose level Maintain dose level 3 (7–9 stools/day > pretx) Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 (≥10 stools/day > pretx) Omit dose until resolved to ≤ grade 2 then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2 Other nonhematologic Excludes alopecia, anorexia, asthenia toxicities 1 Maintain dose level Maintain dose level Maintain dose level 2 ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 3 Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2

2.3 Dosage in Patients With Reduced UGT1A1 Activity

2.3 Dosage in Patients With Reduced UGT1A1 Activity When administered in combination with other agents, or as a single-agent, consider a reduction in the starting dose by at least one level of CAMPTOSAR for patients known to be homozygous for the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or compound heterozygous for the UGT1A1*28 and *6 alleles (*6/*28) [see Dosage and Administration (2.1, 2.2), Warnings and Precautions (5.3), and Clinical Pharmacology (12.3, 12.5)]. Subsequent dosage modifications may be required based on individual patient tolerance to treatment [see Dosage and Administration (2.1, 2.2)].

2.4 Premedication

2.4 Premedication It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as a 5-HT 3 blocker (e.g., ondansetron or granisetron).

Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of CAMPTOSAR. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. A similar antiemetic regimen should be used with CAMPTOSAR in combination therapy.

Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms.

2.5 Preparation of Infusion Solution

2.5 Preparation of Infusion Solution Inspect vial contents for particulate matter and discoloration and repeat inspection when drug product is withdrawn from vial into syringe. CAMPTOSAR Injection 20 mg/mL is intended for single use only and any unused portion should be discarded. CAMPTOSAR Injection must be diluted prior to infusion using aseptic technique.

CAMPTOSAR should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution. Prepare the infusion solution immediately prior to use and commence infusion as soon as possible after preparation.

If visible particulates are present in the infusion solution discard. If it is not possible to use the infusion solution immediately, the infusion solution may be stored for up to 24 hours at 2 °C to 8 °C or discarded.

2.6 Safe Handling

2.6 Safe Handling CAMPTOSAR is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Care should be exercised in the handling and preparation of infusion solutions prepared from CAMPTOSAR Injection. The use of gloves is recommended. If a solution of CAMPTOSAR contacts the skin, wash the skin immediately and thoroughly with soap and water.

If CAMPTOSAR contacts the mucous membranes, flush thoroughly with water.

2.7 Extravasation

2.7 Extravasation Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sterile water and applications of ice are recommended.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.6 Renal Impairment The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, use caution in patients with impaired renal function. CAMPTOSAR is not recommended for use in patients on dialysis.

Patients with Renal Impairment The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations.

Therefore, use caution when administering CAMPTOSAR to patients with hepatic impairment. The tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [see Dosage and Administration (2.1), Warnings and Precautions (5.10) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The effectiveness of irinotecan in pediatric patients has not been established. Results from two open-label, single arm studies were evaluated. One hundred and seventy children with refractory solid tumors were enrolled in one phase 2 trial in which 50 mg/ m 2 of irinotecan was infused for 5 consecutive days every 3 weeks.

Grade 3–4 neutropenia was experienced by 54 (31.8%) patients. Neutropenia was complicated by fever in 15 (8.8%) patients. Grade 3–4 diarrhea was observed in 35 (20.6%) patients. This adverse event profile was comparable to that observed in adults. In the second phase 2 trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m 2 of irinotecan was infused for 5 consecutive days on weeks 0, 1, 3 and 4.

This single agent therapy was followed by multimodal therapy. Accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%). The adverse event profile was different in this study from that observed in adults; the most significant grade 3 or 4 adverse events were dehydration experienced by 6 patients (28.6%) associated with severe hypokalemia in 5 patients (23.8%) and hyponatremia in 3 patients (14.3%); in addition Grade 3–4 infection was reported in 5 patients (23.8%) (across all courses of therapy and irrespective of causal relationship).

Pharmacokinetic parameters for irinotecan and SN-38 were determined in 2 pediatric solid-tumor trials at dose levels of 50 mg/m 2 (60-min infusion, n=48) and 125 mg/m 2 (90-min infusion, n=6). Irinotecan clearance (mean ± S.D.) was 17.3 ± 6.7 L/h/m 2 for the 50mg/m 2 dose and 16.2 ± 4.6 L/h/m 2 for the 125 mg/m 2 dose, which is comparable to that in adults.

Dose-normalized SN-38 AUC values were comparable between adults and children. Minimal accumulation of irinotecan and SN-38 was observed in children on daily dosing regimens [daily × 5 every 3 weeks or (daily × 5) × 2 weeks every 3 weeks].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Patients greater than 65 years of age should be closely monitored because of a greater risk of early and late diarrhea in this population [see Clinical Pharmacology (12.3) and Adverse Reactions (6.1)]. The starting dose of CAMPTOSAR in patients 70 years and older for the once-every-3-week-dosage schedule should be 300 mg/m 2 [see Clinical Pharmacology (12.3) and Dosage and Administration (2)].

The frequency of grade 3 and 4 late diarrhea by age was significantly greater in patients ≥65 years than in patients <65 years (40% [53/133] versus 23% [40/171]; p=0.002). In another study of 183 patients treated on the weekly schedule, the frequency of grade 3 or 4 late diarrhea in patients ≥65 years of age was 28.6% [26/91] and in patients <65 years of age was 23.9% [22/92].

Administration

2.2 Colorectal Single Agent Regimens 1 and 2 Administer CAMPTOSAR as a 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3. A reduction in the starting dose by one dose level of CAMPTOSAR may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients. Table 3. Single-Agent Regimens of CAMPTOSAR and Dose Modifications Regimen 1 (weekly) Subsequent doses may be adjusted as high as 150 mg/m 2 or to as low as 50 mg/m 2 in 25 to 50 mg/m 2 decrements depending upon individual patient tolerance. 125 mg/m 2 intravenous infusion over 90 minutes, days 1,8,15,22 then 2-week rest Starting Dose and Modified Dose Levels Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. (mg/m 2 ) Starting Dose Dose Level -1 Dose Level -2 125 100 75 Regimen 2 (every 3 weeks) Subsequent doses may be adjusted as low as 200 mg/m 2 in 50 mg/m 2 decrements depending upon individual patient tolerance. 350 mg/m 2 intravenous infusion over 90 minutes, once every 3 weeks Starting Dose and Modified Dose Levels (mg/m 2 ) Starting Dose Dose Level -1 Dose Level -2 350 300 250 Dose Modifications Based on recommended dose-levels described in Table 3, Single-Agent Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity. Table 4. Recommended Dose Modifications For Single-Agent Schedules All dose modifications should be based on the worst preceding toxicity A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm 3 , and the platelet count has recovered to ≥100,000/mm 3 , and treatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing CAMPTOSAR. Worst Toxicity NCI Grade National Cancer Institute Common Toxicity Criteria (version 1.0) (Value) During a Cycle of Therapy At the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with the Starting Dose in the Previous Cycle Weekly Weekly Once Every 3 Weeks No toxicity Maintain dose level ↑ 25 mg/m 2 up to a maximum dose of 150 mg/m 2 Maintain dose level Neutropenia 1 (1500 to 1999/mm 3 ) Maintain dose level Maintain dose level Maintain dose level 2 (1000 to 1499/mm 3 ) ↓ 25 mg/m 2 Maintain dose level Maintain dose level 3 (500 to 999/mm 3 ) Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 (<500/mm 3 ) Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2 Neutropenic fever Omit dose until resolved, then ↓ 50 mg/m 2 when resolved ↓ 50 mg/m 2 ↓ 50 mg/m 2 Other hematologic toxicities Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above. Diarrhea 1 (2–3 stools/day > pretx Pretreatment ) Maintain dose level Maintain dose level Maintain dose level 2 (4–6 stools/day > pretx) ↓ 25 mg/m 2 Maintain dose level Maintain dose level 3 (7–9 stools/day > pretx) Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 (≥10 stools/day > pretx) Omit dose until resolved to ≤ grade 2 then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2 Other nonhematologic Excludes alopecia, anorexia, asthenia toxicities 1 Maintain dose level Maintain dose level Maintain dose level 2 ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 3 Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m 2 ↓ 25 mg/m 2 ↓ 50 mg/m 2 4 Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m 2 ↓ 50 mg/m 2 ↓ 50 mg/m 2

2.5 Preparation of Infusion Solution Inspect vial contents for particulate matter and discoloration and repeat inspection when drug product is withdrawn from vial into syringe. CAMPTOSAR Injection 20 mg/mL is intended for single use only and any unused portion should be discarded. CAMPTOSAR Injection must be diluted prior to infusion using aseptic technique. CAMPTOSAR should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution. Prepare the infusion solution immediately prior to use and commence infusion as soon as possible after preparation. If visible particulates are present in the infusion solution discard. If it is not possible to use the infusion solution immediately, the infusion solution may be stored for up to 24 hours at 2 °C to 8 °C or discarded.

2.7 Extravasation Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sterile water and applications of ice are recommended.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 20 mg/mL
  • ) concentrate solution for iv infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (300 mg/15 mL, 20 mg/mL (40 mg/2 mL
  • ) solution for injection: 20 mg/mL ( 40 mg/2 mL and 100 mg/5 mL, 20 mg/mL (100 mg/5 mL, 20 mg/mL (40 mg/2 mL
  • Solution for iv infusion: 20 mg/mL
  • ) concentrate for solution for infusion: 20 mg/mL (40 mg/2 mL and 100 mg/5 mL
  • ) concentrate solution for injection for i.v. infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (300 mg/15 mL, 20 mg/mL (500 mg/25 mL
  • ) concentrate solution for intravenous infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (500 mg/25 mL
  • Concentrate solution for iv infusion: 20 mg/mL
  • ) concentrate solution for i.v. infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (40 mg/2 mL
  • ) solution for intravenous infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (40 mg/2 mL

and 5 more forms; see the products table.

Registered products in the Philippines

46 products registered with the Food and Drug Administration (FDA) Philippines list Irinotecan as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Irinotecan HC1 (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products46
Philippine FDA-registered products for Irinotecan
Package insert
CanisarIrinotecan Hydrochloride
20 mg/mL Concentrate Solution for IV Infusion.USP Type I amber glass vial x 2 mL and 5 mL, grey butyl rubber stopper, aluminum seal, and green plastic flip-off cap (for 2 mL) and purple plastic flip-off cap (for 5 ml) in plastic tray (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company Limited.China
Oncolife Corporation
DR-XY49117
Jun 28, 2029
Fin-OtecanIrinotecan Hydrochloride Trihydrate
20 mg/mL (100 mg/5 mL) Concentrate Solution for IV Infusion5 mL Type I amber glass vial with grey butyl rubber stopper, green flip-off cap, and aluminum seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Finstad Inc.
DRP-14997
Mar 6, 2029
IcanIrinotecan hydrochloride
20 mg/mL Solution for Injection (IV)40 mg/2 mL USP Type I Amber Glass Tubular Vial per box, and 100 mg/5 mL USP Type I Amber Glass Tubular Vial per box
RxVAT-exempt
Venus Remedies, LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116
Nov 3, 2027
ImatiplexIrinotecan hydrochloride (as trihydrate)
20 mg/mL (100 mg/5 mL) Concentrate Solution for I.V. InfusionUSP Type I amber tubular glass vial with grey bromobutyl rubber stopper and aluminum flip off light blue color seal x 5 mL (net content). Box of 1's.
RxVAT-exempt
Shilpa Medicare Limited - Unit 4 Pharmaceutical Formulation SezIndia
Ambica International Corporation
DRP-12370
Jul 27, 2027
InfuirinoIrinotecan Hydrochloride Trihydrate
1.5 mg/mL (270 mg/180 mL), (300 mg/200 mL), (315 mg/210 mL), (330 mg/220 mL, (360 mg/240 mL) Solution for IV Infusion300 mL-capacity Infusion bag with minitulipe stopper wrapped in aluminium pouch x 180 mL, 200 mL, 210 mL, 220 mL, 240 mL (Box of 1's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines Inc.
DR-XY48854
Aug 24, 2028
InsvexIrinotecan hydrochloride (as trihydrate)
20 mg/mL (40 mg/2 mL) Concentrate Solution for IV Infusion4 mL USP Type I Amber Colored Glass Vial with Gray Butyl Rubber Plugs and Blue-Green Flip-off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences
DR-XY49029
Mar 27, 2029
IrebeneIrinotecan (as hydrochloride)
20 mg/mL (40 mg/2mL and 100 mg/5 mL) Concentrate for Solution for Infusion (IV)Amber Tubular USP Type I Glass Vial with bromobutyl rubber stopper, aluminum seal and dark blue flip -off cap x 2 mL and 5 mL (Box of 1's)
RxVAT-exempt
Therdose Pharma Pvt. Ltd.India
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-6564-03
Feb 8, 2032
IricanIrinotecan hydrochloride
20 mg/mL Concentrate Solution for IV InfusionType I Amber Glass vial with Bromobutyl Rubber Stopper and Polypropylene Aluminum Flip-Off Seal (Box of 1 Vial x 2 mL; Box of 1 Vial x 5 mL in 7 mL- capacity)
RxVAT-exempt
Jiangsu Hengrui Medicine Co., Ltd.China
Phil. Pharmawealth, Inc.
DR-XY48013
May 12, 2030
IricanIrinotecan hydrochloride trihydrate
20 mg/mL Solution for Injection (I.V. Infusion)2mL USP Type I, Amber-Colored Glass Vial with 20mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Overseal (2mL with Green Flip-off Seal) (Box of 1's); 5mL USP Type I, Amber-Colored Glass Vial with 20mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Overseal (5mL with Blue Flip-off Seal) (Box of 1's)
RxVAT-exempt
Fresenius Kabi Oncology LimitedIndia
Fresenius Kabi Philippines, Inc.
DR-XY41775
Mar 11, 2031
IrifreeIrinotecan hydrochloride
20mg/mL Solution for Injection (IV)40mg/2mL USP Type I Amber Glass Tubular Vial per box and 100mg/5mL USP Type I Amber Glass Tubular Vial per box
RxVAT-exempt
Venus Remedies, LimitedIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116-03
Nov 3, 2027
IrigenIrinotecan Hydrochloride
20 mg/mL Solution for Injection (IV)40 mg/2 mL USP Type I Amber Glass Tubular Vial per Box and 100 mg/5 mL USP Type I Amber Glass Tubular Vial per Box
RxVAT-exempt
Venus Remedies, LimitedIndia
Genace Pharma DistributorImporter: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116-02
Nov 3, 2027
IrimedIrinotecan HC1Variant spelling
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)Type I Amber Glass Vial with Rubber Stopper and Yellow Flip-off Seal x 5 mL (Box of 1's)
Rx
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DRP-16650
May 28, 2030
IrinoIrinotecan
20 mg/mL Concentrate Solution for IV InfusionType I Amber Glass vial with Grey Chlorobutyl Rubber Stopper and Aluminum Shell with Blue Cap x 5 mL (Box of 1's)
RxVAT-exempt
TTY Biopharm Company Limited Chungli FactoryTaiwan
American Taiwan Biopharma Philippines Inc
DR-XY46072
Oct 6, 2029
Irinocan 100Irinotecan hydrochloride trihydrate
100mg/5mL Concentrate Solution for Infusion (IV)5mL USP Type I amber tubular class vial with chlorobutyl rubber stopper and aluminum flip off orange seal (Box of 1's)
RxVAT-exempt
INTAS PHARMACEUTICALS LTD.India
Accord Healthcare Limited - Philippine Branch Office
DRP-7392
Oct 6, 2027
Irinocan 40Irinotecan hydrochloride trihydrate
40mg/2mL Concentrate Solution for Infusion (IV)5mL USP Type I Amber tubular glass vial with chlorobutyl rubber stopper and aluminum flip off orange seal (Box of 1's)
RxVAT-exempt
INTAS PHARMACEUTICALS LIMITEDIndia
Accord Healthcare Limited - Philippine Branch Office
DR-XY46075
Oct 6, 2027
IrinogenIrinotecan hydrochloride (as trihydrate)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 5 mL with Flip-Off Seal and Rubber Stopper (Box of 1's)
RxVAT-exempt
Laboratorio Kemex S.A.Argentina
AMB HK Enterprises Inc.Trader: Bioprofarma Bago S.A.
DRP-16926
Aug 27, 2030
IrinovidIrinotecan Hydrochloride Trihydrate
20 mg/mL (40 mg/ 2 mL and 100 mg/5 mL) Concentrate for Solutions for IV Infusion2 mL (net content) in 2 mL-capacity amber glass vial sealed with 13 mm butyl coated rubber stopper and sealed with aluminum-plastic cap (Box of 1's); 5 mL (net content) in 6 mL-capacity amber glass vial sealed with 20 mm butyl coated rubber stopper and aluminum-plastic cap (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical (Hainan) Co., Ltd.China
Hovid Inc.Trader: Hovid Bhd.
DR-XY46926
Jun 29, 2030
IritanzIrinotecan Hydrochloride
20 mg / mL Solution for IV InfusionType I Borosilicate Amber Glass Vial x 2 mL with butyl coated rubber stopper and aluminum-plastic cap (Box of 4’s)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-8858
Jul 2, 2030
IritanzIrinotecan Hydrochloride
20 mg / mL Solution for IV Infusion6 mL- capacity Type I Borosilicate Amber Glass Vial x 5 mL with butyl coated rubber stopper and aluminum-plastic cap (Box of 2’s)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-8859
Jul 2, 2030
IriteroIrinotecan (as hydrochloride)
100 mg/5 mL Solution for Intravenous InfusionIn a 5 mL-capacity Glass Vial x 5 mL with gray colored rubber stopper and rust colored flip-off seal (Box of 1's)
RxVAT-exempt
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-8211
May 31, 2029
IriteroIrinotecan (as hydrochloride)
40 mg/2 mL Solution for Intravenous InfusionIn a 5 mL-capacity Glass Vial x 2 mL with grey colored rubber stopper and golden yellow flip-off seal (Box of 1's)
RxVAT-exempt
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-8210
May 31, 2029
Irixarri-100Irinotecan Hydrochloride (as trihydrate)
20mg/mL (100 mg/5 mL) Concentrate Solution For I.V InfusionUSP Type I Amber Colored Glass Vial with Grey Bromobutyl Rubber Plug sealed with Flip-off Green Colored seal x 5 mL (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Ambica International Corporation
DRP-13063
Nov 24, 2027
Irixarri-40Irinotecan (as Hydrochloride Trihydrate)
20 mg/mL (40 mg/2 mL) Concentrate Solution for IV Infusion2 mL in 5 mL-capacity USP Type I amber glass vial with grey bromobutyl rubber stopper and brown flip-off seal (Box of 1 vial x 2 mL)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13160
Dec 12, 2027
IrixtarIrinotecan hydrochloride
20 mg/mL Solution for Injection (IV)40 mg/2 mL USP Type I Amber Glass Tubular Vial per box and 100 mg/5 mL USP Type I Amber Glass Tubular Vial per box
RxVAT-exempt
Venus Remedies, LimitedIndia
Pharmastar Int'l Trading Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116-05
Nov 3, 2027
Irnizet 100Irinotecan Hydrochloride
20 mg/ mL (100 mg/ 5 mL) Concentrate Solution for Injection for I.V. InfusionType I tubular amber glass vial with gray bromobutyl rubber stopper and aluminum seal with polypropylene disc x 5 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialities LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Limited
DRP-12775
Oct 6, 2027
Irnizet 300Irinotecan Hydrochloride
20 mg/mL (300 mg/15 mL) Concentrate Solution for Injection for I.V. InfusionType I tubular amber glass vial with gray bromobutyl rubber stopper and aluminum seal with polypropylene disc x 15 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialities LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Limited
DRP-12774
Oct 6, 2027
Irnizet 40Irinotecan (as hydrochloride)
20 mg/mL (40 mg/ 2 mL) Concentrate Solution for I.V. InfusionType I Tubular Amber Glass Vial with Bromo Butyl stopper and Aluminium seal with Polypropylene Disc x 2 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialties LimitedIndia
MedEthix, Inc.Trader: Aurobindo Pharma Pvt. Ltd.
DRP-13145
Dec 7, 2027
Irnizet 500Irinotecan Hydrochloride
20 mg/mL (500 mg/25 mL) Concentrate Solution for Injection for I.V. InfusionType I tubular amber glass vial with gray bromobutyl rubber stopper and aluminum seal with polypropylene disc x 25 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialities LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Limited
DRP-12773
Oct 6, 2027
IrnocelIrinotecan hydrochloride (as Trihydrate)
20 mg/mL ( 40 mg/2 mL and 100 mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass Vial with Red Flip-Off Seal in 2 mL and 5 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-5456
Aug 18, 2029
IrnotherIrinotecan hydrochloride (as trihydrate)
20 mg/mL (40 mg/2 mL and 100 mg/5 mL) Concentrate for Solution for Infusion (IV)Amber Tubular USP Type I Glass Vial with bromobutyl rubber stopper, aluminum seal and dark blue flip-off cap x 2 mL and 5 mL (Box of 1's)
RxVAT-exempt
Therdose Pharma Pvt. Ltd.India
Medethix, Inc.
DRP-6564
Mar 18, 2031
NoneIrinotecan Hydrochloride (as trihydrate)
20 mg/mL (100 mg/ 5 mL) Solution for Intravenous Infusion5 mL (net content) in 6 mL-capacity brown borosilicate glass vial sealed with 20 mm butyl coated rubber stopper and aluminum plastic cap (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical Co., Ltd.China
Ambica International Corporation
DRP-9853
Jul 15, 2031
NoneIrinotecan Hydrochloride (as trihydrate)
20 mg/mL (40 mg/2 mL) Solution for Intravenous Infusion2 mL (net content) in 2 mL-capacity brown borosilicate glass vial sealed with 13 mm butyl coated rubber stopper and aluminum plastic cap (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical Co., Ltd.China
Ambica International Corporation
DRP-9854
Jul 15, 2031
RinowelIrinotecan hydrochloride
20 mg/mL (100 mg/5 mL) Solution for IV InfusionUSP Type I Amber Glass Vial with Grey Colored Rubber Closure and Aluminum Yellow Flip-off Cap x 5 mL (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ambica International Corporation
DRP-18684
Aug 24, 2031
RoteqanIrinotecan Hydrochloride
20 mg/mL Solution for IV Infusion5 mL USP Type I Amber Tubular Glass Vial with bromobutyl omniflex plus coated rubber stopper and light blue aluminum flip-off seal Box of 1’s
RxVAT-exempt
Shilpa Medicare Limited,India
Ambica International Corporation
DRP-8889
Oct 31, 2030
TopoblockIrinotecan Hydrochloride
20mg/mL Solution for Injection (IV)40mg/2mL USP Type I amber glass amber tubular vial per box and 100mg/5mL USP Type I amber glass tubular vial per box
RxVAT-exempt
Venus Remedies, LimitedIndia
QUALIMED PHARMA INC.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116-01
Nov 3, 2027
TropicanIrinotecan Hydrochloride
20 mg/mL Solution for Injection (IV)40 mg/2 mL USP Type I Amber Glass tubular vial per box and 100mg/5mL USP Type I Amber Glass Tubular vial per box (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-4116-04
Nov 3, 2027
UnbrandedIrinotecan Hydrochloride
20 mg/mL (40 mg/2mL and 100 mg/5mL) Concentrate for Solution for Infusion (IV)Amber Tubular USP Type I Glass Vial with Bromobutyl Rubber Stopper, Aluminum Seal and Dark Blue Flip-off Cap x 2mL and 5mL (Box of 1's)
RxVAT-exempt
Therdose Pharma Pvt. LtdIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-6564-01
Mar 18, 2031
VenteraIrinotecan Hydrochloride
20 mg / mL Solution for IV InfusionType I Borosilicate Amber Glass Vial x 2 mL with butyl coated rubber stopper and aluminum-plastic cap (Box of 4’s)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
Unilab, Inc.Importer: Ambica International Corporation
DRP-8858-01
Jul 2, 2030
VenteraIrinotecan Hydrochloride
20 mg/mL Solution for IV Infusion6 mL-capacity Type I Borosilicate Amber Glass Vial x 5 mL with butyl coated rubber stopper and aluminum plastic cap (Box of 2’s)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
UNILAB, Inc.Importer: Ambica International Corporation
DRP-8859-01
Jul 2, 2030
Zerinov 100Irinotecan Hydrochloride
20 mg/mL (100 mg/ 5 mL) Solution For Injection (Iv)Type-I Amber Glass Vial Sealed with Fray Bromobutyl Rubber Stopper and Aluminum Seal with Yellow Flip-off Cap x 5 mL (Box Of 1'S. Box Of 5'S, Box Of 10'S)
RxVAT-exempt
Cosmas Research Lab Ltd.India
Medinova Pharmaceutical Inc.
DRP-18387
Jun 29, 2031
Zerinov 40Irinotecan hydrochloride
20 mg/mL (40 mg/2 mL) Solution for Injection (IV)Type-I Amber Glass Vial sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Blue Flip-off Cap Ã- 2 mL (Box of 1's, 5's, and 10's)
RxVAT-exempt
Cosmas Research Lab Ltd.India
Medinova Pharmaceutical Inc.
DRP-18475
Jul 21, 2031
(no brand name)Irinotecan (as hydrochloride)
20 mg/ mL (500 mg/ 25 mL) Concentrate Solution for Intravenous (I.V.) InfusionType I Tubular Glass Vial with Bromobutyl Rubber Stopper and Aluminum Seal x 25 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialties LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Pvt. Ltd.
DRP-12824
Oct 11, 2027
(no brand name)Irinotecan Hydrochloride
20 mg/mL (100 mg/5 mL) Concentrate Solution for Intravenous InfusionType I tubular amber glass vial with gray bromobutyl rubber stopper and aluminum seal with sky blue polypropylene disc x 5. SC x 5 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialities LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Limited
DRP-13907
May 16, 2028
(no brand name)Irinotecan hydrochloride
20 mg/mL (100 mg/5 mL) Concentrate Solution for Intravenous Infusion.Shrink-wrapped Type I Amber Glass Vial with grey butyl elastomeric closure and aluminum seal with green plastic flip-off top x 5 mL (Box of 1's)
RxVAT-exempt
Zydus Hospira Oncology Pvt. Ltd.India
Importer: Pfizer, Inc.
DRP-7416
Jun 4, 2029
(no brand name)Irinotecan Hydrochloride (as trihydrate)
20 mg/mL (100 mg/5 mL) Concentrate Solution for IV InfusionType I amber glass vial with grey bromobutyl rubber stopper, aluminum seal, and light blue flip-off cap (Box of 1's)
RxVAT-exempt
Shilpa Medicare Limited (Unit-4, Pharmaceutical Formulations Sez)India
Biocare Lifesciences, Inc.
DRP-14807
Jan 12, 2029
(no brand name)Irinotecan Hydrochloride
20 mg/mL (300 mg/15 mL) Concentrate Solution For IV InfusionType I tubular amber glass vial with gray bromobutyl rubber stopper and aluminum seal with sky blue polypropylene disc x 15 mL (Box of 1's)
RxVAT-exempt
Eugia Pharma Specialities LimitedIndia
Medethix, Inc.Trader: Aurobindo Pharma Ltd.
DRP-13449
Feb 22, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 40 mg/2 mL (20 mg/mL), 100 mg/5 mL (20 mg/mL), and 300 mg/15 mL (20 mg/mL) sterile, pale yellow, clear, aqueous solution in a single-dose vial. Injection: 40 mg/2 mL (20 mg/mL), 100 mg/5 mL (20 mg/mL), and 300 mg/15 mL (20 mg/mL) solution in a single-dose vial. (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Diarrhea and Cholinergic Reactions: Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is usually transient and may be accompanied by cholinergic symptoms. Consider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated). Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can occur. Monitor and replace fluid and electrolytes. Treat with loperamide. Use antibiotic support for ileus and fever. Interrupt CAMPTOSAR and reduce subsequent doses if severe diarrhea occurs. (5.1)
  • • Myelosuppression: Manage promptly with antibiotic support. Interrupt CAMPTOSAR and reduce subsequent doses if necessary. (5.2)
  • • Increased Risk of Neutropenia in Patients With Reduced UGT1A1 Activity: Individuals with UGT1A1*28/*28, or *6/*6, or *6/*28 genotypes are at increased risk for severe neutropenia during CAMPTOSAR treatment. (5.3)
  • • Hypersensitivity: Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue CAMPTOSAR if this occurs. (5.4)
  • • Renal Impairment/Renal Failure: Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea. (5.5)
  • • Pulmonary Toxicity: Interstitial Pulmonary Disease …
5.1 Diarrhea and Cholinergic Reactions

5.1 Diarrhea and Cholinergic Reactions Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.

Bradycardia may also occur. Early diarrhea and other cholinergic symptoms may be prevented or treated. Consider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated). These symptoms are expected to occur more frequently with higher irinotecan doses.

Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Grade 3–4 late diarrhea occurred in 23–31% of patients receiving weekly dosing. In the clinical studies, the median time to the onset of late diarrhea was 5 days with 3-week dosing and 11 days with weekly dosing.

Late diarrhea can be complicated by colitis, ulceration, bleeding, ileus, obstruction, and infection. Cases of megacolon and intestinal perforation have been reported. Patients should have loperamide readily available to begin treatment for late diarrhea. Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal.

One dosage regimen for loperamide is 4 mg at the first onset of late diarrhea and then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. During the night, the patient may take 4 mg of loperamide every 4 hours.

Monitor and replace fluid and electrolytes. Use antibiotic support for ileus, fever, or severe neutropenia. Subsequent weekly chemotherapy treatments should be delayed in patients until return of pretreatment bowel function for at least 24 hours without anti-diarrhea medication. Patients must not be treated with CAMPTOSAR until resolution of the bowel obstruction.

If grade 2, 3, or 4 late diarrhea recurs, subsequent doses of CAMPTOSAR should be decreased [see Dosage and Administration (2)]. Avoid diuretics or laxatives in patients with diarrhea.

5.2 Myelosuppression

5.2 Myelosuppression CAMPTOSAR can cause severe myelosuppression. Bacterial, viral, and fungal infections have occurred in patients treated with CAMPTOSAR. Deaths due to sepsis following severe neutropenia have been reported in patients treated with CAMPTOSAR. In the clinical studies evaluating the weekly dosage schedule, neutropenic fever (concurrent NCI grade 4 neutropenia and fever of grade 2 or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of neutropenia.

Manage febrile neutropenia promptly with antibiotic support [see Warnings and Precautions (5.2)]. Hold CAMPTOSAR if neutropenic fever occurs or if the absolute neutrophil count drops <1000/mm 3. After recovery to an absolute neutrophil count ≥1000/mm 3, subsequent doses of CAMPTOSAR should be reduced [see Dosage and Administration (2)].

When evaluated in the trials of weekly administration, the frequency of grade 3 and 4 neutropenia was higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation (48% [13/27] versus 24% [67/277]; p=0.04). Patients who have previously received pelvic/abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR.

Based on sparse available data, the concurrent administration of CAMPTOSAR with irradiation is not recommended. Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more also had a greater likelihood of experiencing first-cycle grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/266]; p<0.001).

Patients with deficient glucuronidation of bilirubin, such as those with Gilbert's syndrome, may be at greater risk of myelosuppression when receiving therapy with CAMPTOSAR [see Warnings and Precautions (5.3)].

5.3 Increased Risk of Neutropenia in Patients With Reduced UGT1A1 Activity

5.3 Increased Risk of Neutropenia in Patients With Reduced UGT1A1 Activity Published studies have shown that individuals who are homozygous for either the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or who are compound or double heterozygous for the UGT1A1*28 and *6 alleles (*6/*28) are at increased risk for severe or life-threatening neutropenia during treatment with CAMPTOSAR. These individuals are UGT1A1 poor metabolizers and experience increased systemic exposure to SN-38, an active metabolite of irinotecan.

Individuals who are heterozygous for either the UGT1A1*28 or *6 alleles (*1/*28, *1/*6) are intermediate metabolizers and may also have an increased risk of severe or life-threatening neutropenia [see Dosage and Administration (2) and Clinical Pharmacology (12.3, 12.5)]. Consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status [see Clinical Pharmacology (12.5)].

When administering CAMPTOSAR, consider a reduction in the CAMPTOSAR starting dose by at least one level for patients known to be homozygous or compound heterozygous for the UGT1A1*28 and/or *6 alleles (*28/*28, *6/*6, *6/*28). Closely monitor patients with UGT1A1 *28 or *6 alleles for neutropenia during and after treatment with CAMPTOSAR.

The precise dosage reduction in this patient population is not known. Subsequent dosage modifications may be required based on individual patient tolerance to treatment [see Dosage and Administration (2.1, 2.2)].

5.4 Hypersensitivity

5.4 Hypersensitivity Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue CAMPTOSAR if anaphylactic reaction occurs.

5.5 Renal Impairment/Renal Failure

5.5 Renal Impairment/Renal Failure Renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea.

5.6 Pulmonary Toxicity Interstitial

5.6 Pulmonary Toxicity Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred in patients receiving irinotecan (in combination and as monotherapy). Risk factors include pre-existing lung disease, use of pneumotoxic drugs, radiation therapy, and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during CAMPTOSAR therapy.

In Japanese studies, a reticulonodular pattern on chest x-ray was observed in a small percentage of patients. New or progressive, dyspnea, cough, and fever should prompt interruption of chemotherapy, pending diagnostic evaluation. If IPD is diagnosed, CAMPTOSAR and other chemotherapy should be discontinued and appropriate treatment instituted as needed [see Adverse Reactions (6.1)].

5.7 Toxicity of the 5 Day Regimen

5.7 Toxicity of the 5 Day Regimen Outside of a well-designed clinical study, CAMPTOSAR Injection should not be used in combination with a regimen of 5-FU/LV administered for 4–5 consecutive days every 4 weeks because of reports of increased toxicity, including toxic deaths. CAMPTOSAR should be used as recommended in Table 2 [see Dosage and Administration (2)].

5.8 Increased Toxicity in Patients With Performance Status 2

5.8 Increased Toxicity in Patients With Performance Status 2 In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle treatment discontinuation, and early deaths were observed in patients with a baseline performance status of 2 than in patients with a baseline performance status of 0 or 1.

5.9 Embryo-Fetal Toxicity

5.9 Embryo-Fetal Toxicity Based on its mechanism of action and findings in animals, CAMPTOSAR can cause fetal harm when administered to a pregnant woman. In animal studies, intravenous administration of irinotecan during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on area under the curve (AUC) at the clinical dose of 125 mg/m 2.

Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception during treatment with CAMPTOSAR and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use condoms during treatment and for 3 months after the final dose of CAMPTOSAR [see Use in Specific Populations (8.1), (8.3) and Nonclinical Toxicology (13.1)].

5.10 Patients With Hepatic Impairment

5.10 Patients With Hepatic Impairment The use of CAMPTOSAR in patients with significant hepatic impairment has not been established. In clinical trials of either dosing schedule, irinotecan was not administered to patients with serum bilirubin >2.0 mg/dL, or transaminase >3 times the upper limit of normal if no liver metastasis, or transaminase >5 times the upper limit of normal with liver metastasis.

In clinical trials of the weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dL) had a significantly greater likelihood of experiencing first-cycle, grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/226]; p<0.001) [see Dosage and Administration (2.1), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Drug interactions

Drug interactions (US label) US FDA label
  • • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (7.2)
  • • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (7.3)
  • 7.1 5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the C max and AUC 0–24 of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended [see Dosage and Administration (2)]. Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted.
7.2 Strong CYP3A4 Inducers

7.2 Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. John's wort. The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined.

Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of CAMPTOSAR therapy. Do not administer strong CYP3A4 inducers with CAMPTOSAR unless there are no therapeutic alternatives.

7.3 Strong CYP3A4 or UGT1A1 Inhibitors

7.3 Strong CYP3A4 or UGT1A1 Inhibitors Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively, [see Clinical Pharmacology (12.3)]. Patients receiving concomitant ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased exposure to irinotecan and its active metabolite SN-38.

Coadministration of CAMPTOSAR with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. Discontinue strong CYP3A4 inhibitors at least 1 week prior to starting CAMPTOSAR therapy.

Do not administer strong CYP3A4 or UGT1A1 inhibitors with CAMPTOSAR unless there are no therapeutic alternatives.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Elimination Metabolism Irinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases that form an active metabolite SN-38, and UGT1A1 which mediates the glucuronidation of SN-38 to form an inactive metabolite.

Patients who are homozygous for either the UGT1A1*28 or *6 alleles, or who are compound heterozygous for these alleles, have higher SN-38 AUC than patients with the wild-type UGT1A1 alleles [see Dosage and Administration (2.3) , Warnings and Precautions (5.3) , and Clinical Pharmacology (12.5) ] .

Irinotecan can also undergo CYP3A4-mediated oxidative metabolism to several inactive metabolites, one of which can be hydrolyzed by carboxylesterase to release the active metabolite SN-38.

Drug Interaction Studies Clinical Studies and Model-Informed Approaches Dexamethasone, a moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan.

7 DRUG INTERACTIONS • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR.

( 7.2 ) • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR.

Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted. 7.2 Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St.

Do not administer strong CYP3A4 inducers with CAMPTOSAR unless there are no therapeutic alternatives. 7.3 Strong CYP3A4 or UGT1A1 Inhibitors Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively, [see Clinical Pharmacology (12.3) ] .

Adverse reactions

Adverse reactions (US label) US FDA label
  • Common adverse reactions (≥30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia. (6.1)
  • Common adverse reactions (≥30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, alopecia. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc, at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Studies Experience

6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Common adverse reactions (≥30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, and alopecia.

Common adverse reactions (≥30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia. First-Line Combination Therapy A total of 955 patients with metastatic colorectal cancer received the recommended regimens of irinotecan in combination with 5-FU/LV, 5-FU/LV alone, or irinotecan alone.

In the two phase 3 studies, 370 patients received irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received irinotecan alone [see Dosage and Administration (2)]. In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received irinotecan alone.

Deaths potentially related to treatment occurred in 2 (0.9%) patients who received irinotecan in combination with 5-FU/LV (2 neutropenic fever/sepsis), 3 (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, 1 CNS bleeding during thrombocytopenia, 1 unknown) and 2 (0.9%) patients who received irinotecan alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received irinotecan alone.

Discontinuations due to adverse events were reported for 17 (7.6%) patients who received irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received irinotecan alone. In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received irinotecan in combination with 5-FU/LV and 4 (2.8%) received 5-FU/LV alone.

There was one potentially treatment-related death, which occurred in a patient who received irinotecan in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for 3 (2.1%) patients who received irinotecan in combination with 5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone.

Discontinuations due to adverse events were reported for 9 (6.2%) patients who received irinotecan in combination with 5FU/LV and 1 (0.7%) patient who received 5-FU/LV alone. The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia.

The most clinically significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade 4 neutropenia, neutropenic fever (defined as grade 2 fever and grade 4 neutropenia), and mucositis were observed less often with weekly irinotecan/5-FU/LV than with monthly administration of 5-FU/LV.

Tables 5 and 6 list the clinically relevant adverse events reported in Studies 1 and 2, respectively. Table 5. Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Severity of adverse events based on NCI CTC (version 1.0) Adverse Event Study 1 Irinotecan + Bolus 5-FU/LV weekly × 4 every 6 weeks N=225 Bolus 5-FU/LV daily × 5 every 4 weeks N=219 Irinotecan weekly × 4 every 6 weeks N=223 Grade 1–4 Grade 3&4 Grade 1–4 Grade 3&4 Grade 1–4 Grade 3&4 TOTAL Adverse Events 100 53.3 100 45.7 99.6 45.7 GASTROINTESTINAL Diarrhea Late 84.9 22.7 69.4 13.2 83.0 31.0 grade 3 -- 15.1 -- 5.9 -- 18.4 grade 4 -- 7.6 -- 7.3 -- 12.6 Early 45.8 4.9 31.5 1.4 43.0

6.7 Nausea 79

6.7 Nausea 79.1 15.6 67.6 8.2 81.6 16.1 Abdominal pain 63.1 14.6 50.2 11.5 67.7 13.0 Vomiting 60.4 9.7 46.1 4.1 62.8 12.1 Anorexia 34.2 5.8 42.0 3.7 43.9 7.2 Constipation 41.3 3.1 31.5 1.8 32.3 0.4 Mucositis 32.4 2.2 76.3 16.9 29.6 2.2 HEMATOLOGIC Neutropenia 96.9 53.8 98.6 66.7 96.4 31.4 grade 3 -- 29.8 -- 23.7 -- 19.3 grade 4 -- 24.0 -- 42.5 -- 12.1 Leukopenia 96.9 37.8 98.6 23.3 96.4 21.5 Anemia 96.9 8.4 98.6 5.5 96.9 4.5 Neutropenic fever -- 7.1 -- 14.6 -- 5.8 Thrombocytopenia 96.0 2.6 98.6 2.7 96.0 1.7 Neutropenic infection -- 1.8 -- 0 -- 2.2 BODY AS A WHOLE Asthenia 70.2 19.5 64.4 11.9 69.1 13.9 Pain 30.7 3.1 26.9 3.6 22.9 2.2 Fever 42.2 1.7 32.4 3.6 43.5 0.4 Infection 22.2 0 16.0 1.4 13.9 0.4 METABOLIC & NUTRITIONAL Bilirubin 87.6 7.1 92.2 8.2 83.9 7.2 DERMATOLOGIC Exfoliative dermatitis 0.9 0 3.2 0.5 0 0 Rash 19.1 0 26.5 0.9 14.3 0.4 Alopecia Complete hair loss = Grade 2 43.1 -- 26.5 -- 46.1 -- RESPIRATORY Dyspnea 27.6 6.3 16.0 0.5 22.0 2.2 Cough 26.7 1.3 18.3 0 20.2 0.4 Pneumonia 6.2 2.7 1.4 1.0 3.6 1.3 NEUROLOGIC Dizziness 23.1 1.3 16.4 0 21.1 1.8 Somnolence 12.4 1.8 4.6 1.8 9.4 1.3 Confusion 7.1 1.8 4.1 0 2.7 0 CARDIOVASCULAR Vasodilatation 9.3 0.9 5.0 0 9.0 0 Hypotension 5.8 1.3 2.3 0.5 5.8 1.7 Thromboembolic events Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. 9.3 -- 11.4 -- 5.4 -- Table 6. Study 2: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Severity of adverse events based on NCI CTC (version 1.0) Adverse Event Study 2 Irinotecan + 5-FU/LV infusional days 1&2 every 2 weeks N= 145 5-FU/LV infusional days 1&2 every 2 weeks N=143 Grades 1–4 Grades 3&4 Grades 1–4 Grades 3&4 TOTAL Adverse Events 100 72.4 100 39.2 GASTROINTESTINAL Diarrhea late 72.4 14.4 44.8 6.3 grade 3 -- 10.3 -- 4.2 grade 4 -- 4.1 -- 2.1 Cholinergic syndrome Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan) 28.3 1.4 0.7 0 Nausea 66.9 2.1 55.2 3.5 Abdominal pain 17.2 2.1 16.8 0.7 Vomiting 44.8 3.5 32.2 2.8 Anorexia 35.2 2.1 18.9 0.7 Constipation 30.3 0.7 25.2 1.4 Mucositis 40.0 4.1 28.7 2.8 HEMATOLOGIC Neutropenia 82.5 46.2 47.9 13.4 grade 3 -- 36.4 -- 12.7 grade 4 -- 9.8 -- 0.7 Leukopenia 81.3 17.4 42.0 3.5 Anemia 97.2 2.1 90.9 2.1 Neutropenic fever -- 3.4 -- 0.7 Thrombocytopenia 32.6 0 32.2 0 Neutropenic infection -- 2.1 -- 0 BODY AS A WHOLE Asthenia 57.9 9.0 48.3 4.2 Pain 64.1 9.7 61.5 8.4 Fever 22.1 0.7 25.9 0.7 Infection 35.9 7.6 33.6 3.5 METABOLIC AND NUTRITIONAL Bilirubin 19.1 3.5 35.9 10.6 DERMATOLOGIC Hand and foot syndrome 10.3 0.7 12.6 0.7 Cutaneous signs 17.2 0.7 20.3 0 Alopecia Complete hair loss = Grade 2 56.6 -- 16.8 -- RESPIRATORY Dyspnea 9.7 1.4 4.9 0 CARDIOVASCULAR Hypotension 3.4 1.4 0.7 0 Thromboembolic events Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. 11.7 -- 5.6 -- Second-Line Single-Agent Therapy Weekly Dosage Schedule In three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with CAMPTOSAR.

Seventeen of the patients died within 30 days of the administration of CAMPTOSAR; in five cases (1.6%, 5/304), the deaths were potentially drug-related. One of the patients died of neutropenic sepsis without fever. Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care. One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of CAMPTOSAR.

The primary reasons for drug-related hospitalization were diarrhea, with or without nausea and/or vomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever (8.2%); and nausea and/or vomiting (4.9%). The first dose of at least one cycle of CAMPTOSAR was reduced for 67% of patients who began the studies at the 125-mg/m 2 starting dose.

Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m 2 dose level. The most common reasons for dose reduction were late diarrhea, neutropenia, and leukopenia. Thirteen (4.3%) patients discontinued treatment with CAMPTOSAR because of adverse events. The adverse events in Table 7 are based on the experience of the 304 patients enrolled in the three studies described in Clinical Studies (14.1).

Table 7. Adverse Events Occurring in >10% of 304 Previously Treated Patients With Metastatic Carcinoma of the Colon or Rectum Severity of adverse events based on NCI CTC (version 1.0) % of Patients Reporting Body System & Event NCI Grades 1–4 NCI Grades 3 & 4 GASTROINTESTINAL Diarrhea (late) Occurring >24 hours after administration of CAMPTOSAR 88 31 7–9 stools/day (grade 3) — (16) ≥10 stools/day (grade 4) — (14) Nausea 86 17 Vomiting 67 12 Anorexia 55 6 Diarrhea (early) Occurring ≤24 hours after administration of CAMPTOSAR 51 8 Constipation 30 2 Flatulence 12 0 Stomatitis 12 1 Dyspepsia 10 0 HEMATOLOGIC Leukopenia 63 28 Anemia 60 7 Neutropenia 54 26 500 to <1000/mm 3 (grade 3) — (15) <500/mm 3 (grade 4) — (12) BODY AS A WHOLE Asthenia 76 12 Abdominal cramping/pain 57 16 Fever 45 1 Pain 24 2 Headache 17 1 Back pain 14 2 Chills 14 0 Minor infection Primarily upper respiratory infections 14 0 Edema 10 1 Abdominal enlargement 10 0 METABOLIC AND NUTRITIONAL ↓ Body weight 30 1 Dehydration 15 4 ↑ Alkaline phosphatase 13 4 ↑ SGOT 10 1 DERMATOLOGIC Alopecia 60 NA Not applicable; complete hair loss = NCI grade 2 Sweating 16 0 Rash 13 1 RESPIRATORY Dyspnea 22 4 ↑ Coughing 17 0 Rhinitis 16 0 NEUROLOGIC Insomnia 19 0 Dizziness 15 0 CARDIOVASCULAR Vasodilation (flushing) 11 0 Once-Every-3-Week Dosage Schedule A total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase 3 studies: 316 received irinotecan, 129 received 5-FU, and 90 received best supportive care.

Eleven (3.5%) patients treated with irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the deaths were potentially related to irinotecan treatment and were attributed to neutropenic infection, grade 4 diarrhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this death was attributed to grade 4 diarrhea.

Hospitalizations due to serious adverse events occurred at least once in 60% (188/316) of patients who received irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events.

Of the 316 patients treated with irinotecan, the most clinically significant adverse events (all grades, 1–4) were diarrhea (84%), alopecia (72%), nausea (70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%). Table 8 lists the grade 3 and 4 adverse events reported in the patients enrolled to all treatment arms of the two studies described in Clinical Studies (14.1).

Table 8. Percent Of Patients Experiencing Grade 3 & 4 Adverse Events In Comparative Studies Of Once-Every-3-Week Irinotecan Therapy Severity of adverse events based on NCI CTC (version 1.0) Study 1 Study 2 Adverse Event Irinotecan N=189 BSC BSC = best supportive care N=90 Irinotecan N=127 5-FU N=129 TOTAL Grade 3/4 Adverse Events 79 67 69 54 GASTROINTESTINAL Diarrhea 22 6 22 11 Vomiting 14 8 14 5 Nausea 14 3 11 4 Abdominal pain 14 16 9 8 Constipation 10 8 8 6 Anorexia 5 7 6 4 Mucositis 2 1 2 5 HEMATOLOGIC Leukopenia/Neutropenia 22 0 14 2 Anemia 7 6 6 3 Hemorrhage 5 3 1 3 Thrombocytopenia 1 0 4 2 Infection without grade 3/4 neutropenia 8 3 1 4 with grade 3/4 neutropenia 1 0 2 0 Fever without grade 3/4 neutropenia 2 1 2 0 with grade 3/4 neutropenia 2 0 4 2 BODY AS A WHOLE Pain 19 22 17 13 Asthenia 15 19 13 12 METABOLIC AND NUTRITIONAL Hepatic Hepatic includes events such as ascites and jaundice 9 7 9 6 DERMATOLOGIC Hand and foot syndrome 0 0 0 5 Cutaneous signs Cutaneous signs include events such as rash 2 0 1 3 RESPIRATORY Respiratory includes events such as dyspnea and cough 10 8 5 7 NEUROLOGIC Neurologic includes events such as somnolence 12 13 9 4 CARDIOVASCULAR Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction 9 3 4 2 OTHER Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss 32 28 12 14 The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).

The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of CAMPTOSAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Myocardial ischemic events have been observed following CAMPTOSAR therapy. Thromboembolic events have been observed in patients receiving CAMPTOSAR. Symptomatic pancreatitis, asymptomatic pancreatic enzyme elevation have been reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver metastasis have been observed.

Hyponatremia, mostly with diarrhea and vomiting, has been reported. Transient dysarthria has been reported in patients treated with CAMPTOSAR; in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of irinotecan. Interaction between CAMPTOSAR and neuromuscular blocking agents cannot be ruled out.

Irinotecan has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarizing drugs may be antagonized. Infections: fungal and viral infections have been reported.

Adverse reaction frequency tables (US label) US FDA label
Table 5. Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination TherapiesSeverity of adverse events based on NCI CTC (version 1.0)
Adverse EventStudy 1
Irinotecan + Bolus 5-FU/LV weekly × 4 every 6 weeks N=225Bolus 5-FU/LV daily × 5 every 4 weeks N=219Irinotecan weekly × 4 every 6 weeks N=223
Grade 1–4Grade 3&4Grade 1–4Grade 3&4Grade 1–4Grade 3&4
TOTAL Adverse Events10053.310045.799.645.7
GASTROINTESTINAL
Diarrhea
Late84.922.769.413.283.031.0
grade 3--15.1--5.9--18.4
grade 4--7.6--7.3--12.6
Early45.84.931.51.443.06.7
Nausea79.115.667.68.281.616.1
Abdominal pain63.114.650.211.567.713.0
Vomiting60.49.746.14.162.812.1
Anorexia34.25.842.03.743.97.2
Constipation41.33.131.51.832.30.4
Mucositis32.42.276.316.929.62.2
HEMATOLOGIC
Neutropenia96.953.898.666.796.431.4
grade 3--29.8--23.7--19.3
grade 4--24.0--42.5--12.1
Leukopenia96.937.898.623.396.421.5
Anemia96.98.498.65.596.94.5
Neutropenic fever--7.1--14.6--5.8
Thrombocytopenia96.02.698.62.796.01.7
Neutropenic infection--1.8--0--2.2
BODY AS A WHOLE
Asthenia70.219.564.411.969.113.9
Pain30.73.126.93.622.92.2
Fever42.21.732.43.643.50.4
Infection22.2016.01.413.90.4
METABOLIC & NUTRITIONAL
Bilirubin87.67.192.28.283.97.2
DERMATOLOGIC
Exfoliative dermatitis0.903.20.500
Rash19.1026.50.914.30.4
AlopeciaComplete hair loss = Grade 243.1--26.5--46.1--
RESPIRATORY
Dyspnea27.66.316.00.522.02.2
Cough26.71.318.3020.20.4
Pneumonia6.22.71.41.03.61.3
NEUROLOGIC
Dizziness23.11.316.4021.11.8
Somnolence12.41.84.61.89.41.3
Confusion7.11.84.102.70
CARDIOVASCULAR
Vasodilatation9.30.95.009.00
Hypotension5.81.32.30.55.81.7
Thromboembolic eventsIncludes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.9.3--11.4--5.4--
Table 6. Study 2: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination TherapiesSeverity of adverse events based on NCI CTC (version 1.0)
Adverse EventStudy 2
Irinotecan + 5-FU/LV infusional days 1&2 every 2 weeks N= 1455-FU/LV infusional days 1&2 every 2 weeks N=143
Grades 1–4Grades 3&4Grades 1–4Grades 3&4
TOTAL Adverse Events10072.410039.2
GASTROINTESTINAL
Diarrhea
late72.414.444.86.3
grade 3--10.3--4.2
grade 4--4.1--2.1
Cholinergic syndromeIncludes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan)28.31.40.70
Nausea66.92.155.23.5
Abdominal pain17.22.116.80.7
Vomiting44.83.532.22.8
Anorexia35.22.118.90.7
Constipation30.30.725.21.4
Mucositis40.04.128.72.8
HEMATOLOGIC
Neutropenia82.546.247.913.4
grade 3--36.4--12.7
grade 4--9.8--0.7
Leukopenia81.317.442.03.5
Anemia97.22.190.92.1
Neutropenic fever--3.4--0.7
Thrombocytopenia32.6032.20
Neutropenic infection--2.1--0
BODY AS A WHOLE
Asthenia57.99.048.34.2
Pain64.19.761.58.4
Fever22.10.725.90.7
Infection35.97.633.63.5
METABOLIC AND NUTRITIONAL
Bilirubin19.13.535.910.6
DERMATOLOGIC
Hand and foot syndrome10.30.712.60.7
Cutaneous signs17.20.720.30
AlopeciaComplete hair loss = Grade 256.6--16.8--
RESPIRATORY
Dyspnea9.71.44.90
CARDIOVASCULAR
Hypotension3.41.40.70
Thromboembolic eventsIncludes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.11.7--5.6--
Table 7. Adverse Events Occurring in >10% of 304 Previously Treated Patients With Metastatic Carcinoma of the Colon or RectumSeverity of adverse events based on NCI CTC (version 1.0)
% of Patients Reporting
Body System & EventNCI Grades 1–4NCI Grades 3 & 4
GASTROINTESTINAL
Diarrhea (late)Occurring >24 hours after administration of CAMPTOSAR8831
7–9 stools/day (grade 3)—(16)
≥10 stools/day (grade 4)—(14)
Nausea8617
Vomiting6712
Anorexia556
Diarrhea (early)Occurring ≤24 hours after administration of CAMPTOSAR518
Constipation302
Flatulence120
Stomatitis121
Dyspepsia100
HEMATOLOGIC
Leukopenia6328
Anemia607
Neutropenia5426
500 to <1000/mm3 (grade 3)—(15)
<500/mm3 (grade 4)—(12)
BODY AS A WHOLE
Asthenia7612
Abdominal cramping/pain5716
Fever451
Pain242
Headache171
Back pain142
Chills140
Minor infectionPrimarily upper respiratory infections140
Edema101
Abdominal enlargement100
METABOLIC AND NUTRITIONAL
↓ Body weight301
Dehydration154
↑ Alkaline phosphatase134
↑ SGOT101
DERMATOLOGIC
Alopecia60NANot applicable; complete hair loss = NCI grade 2
Sweating160
Rash131
RESPIRATORY
Dyspnea224
↑ Coughing170
Rhinitis160
NEUROLOGIC
Insomnia190
Dizziness150
CARDIOVASCULAR
Vasodilation (flushing)110
Table 8. Percent Of Patients Experiencing Grade 3 & 4 Adverse Events In Comparative Studies Of Once-Every-3-Week Irinotecan TherapySeverity of adverse events based on NCI CTC (version 1.0)
Study 1Study 2
Adverse EventIrinotecan N=189BSC BSC = best supportive care N=90Irinotecan N=1275-FU N=129
TOTAL Grade 3/4 Adverse Events79676954
GASTROINTESTINAL
Diarrhea2262211
Vomiting148145
Nausea143114
Abdominal pain141698
Constipation10886
Anorexia5764
Mucositis2125
HEMATOLOGIC
Leukopenia/Neutropenia220142
Anemia7663
Hemorrhage5313
Thrombocytopenia1042
Infection
without grade 3/4 neutropenia8314
with grade 3/4 neutropenia1020
Fever
without grade 3/4 neutropenia2120
with grade 3/4 neutropenia2042
BODY AS A WHOLE
Pain19221713
Asthenia15191312
METABOLIC AND NUTRITIONAL
Hepatic Hepatic includes events such as ascites and jaundice9796
DERMATOLOGIC
Hand and foot syndrome0005
Cutaneous signs Cutaneous signs include events such as rash2013
RESPIRATORY Respiratory includes events such as dyspnea and cough10857
NEUROLOGIC Neurologic includes events such as somnolence121394
CARDIOVASCULAR Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction9342
OTHER Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss32281214

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, CAMPTOSAR can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. Available postmarketing and published data reporting the use of CAMPTOSAR in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

In animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on AUC at the clinical dose of 125 mg/m 2 (see Data). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Radioactivity related to 14 C-irinotecan crosses the placenta of rats following intravenous administration. Intravenous administration of irinotecan to rats at a dose of 6 mg/kg/day (approximately 0.2 times the clinical exposure (AUC) at the 125 mg/m 2 dose based on exposure data from a separate rat study) during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses; at doses ≥ 1.2 mg/kg/day (approximately 0.03 times the clinical exposure (AUC) at the 125 mg/m 2 dose based on exposure data from a separate rat study) there were increases in a variety of external, visceral, and skeletal abnormalities.

Administration of irinotecan to pregnant rabbits at a dose of 6 mg/kg (approximately half of the clinical dose of 125 mg/m 2 based on BSA) resulted in similar findings to those in rats, with increased post-implantation loss, decreased live fetuses, and increased external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring.

Mechanism of action

12.1 Mechanism of Action Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks.

Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines.

In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3)]. The precise contribution of SN-38 to the activity of CAMPTOSAR is thus unknown.

Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form. Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.

The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours.

Excretion The disposition of irinotecan has not been fully elucidated in humans.

The urinary excretion of irinotecan is 11% to 20%;

The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m 2 ) to 50% (300 mg/m 2 ).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of irinotecan and SN-38 are similar to those of total irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium.

Over the recommended dose range of 50 to 350 mg/m 2, the AUC of irinotecan increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within 1 hour following the end of a 90-minute infusion of irinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following a 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m 2 determined in two clinical studies in patients with solid tumors are summarized in Table 9: Table 9.

Summary of Mean (±Standard Deviation) Irinotecan and SN-38 Pharmacokinetic Parameters in Patients With Solid Tumors Dose (mg/m 2) Irinotecan SN-38 C max (ng/mL) AUC 0–24 (ng∙h/mL) t 1/2 (h) V z (L/m 2) CL (L/h/m 2) C max (ng/mL) AUC 0–24 (ng∙h/mL) t 1/2 (h) C max - Maximum plasma concentration AUC 0–24 - Area under the plasma concentration-time curve from time 0 to 24 hours after the end of the 90-minute infusion t 1/2 - Terminal elimination half-life V z - Volume of distribution of terminal elimination phase CL - Total systemic clearance 125 (N=64) 1,660 ±797 10,200 ±3,270 5.8 Plasma specimens collected for 24 hours following the end of the 90-minute infusion. ±0.7 110 ±48.5 13.3 ±6.01 26.3 ±11.9 229 ±108 10.4 ±3.1 340 (N=6) 3,392 ±874 20,604 ±6,027 11.7 Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38. ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).

SN-38 is highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which irinotecan and SN-38 predominantly binds is albumin. Elimination Metabolism Irinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases that form an active metabolite SN-38, and UGT1A1 which mediates the glucuronidation of SN-38 to form an inactive metabolite.

SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38. Patients who are homozygous for either the UGT1A1*28 or *6 alleles, or who are compound heterozygous for these alleles, have higher SN-38 AUC than patients with the wild-type UGT1A1 alleles [see Dosage and Administration (2.3), Warnings and Precautions (5.3), and Clinical Pharmacology (12.5)].

Irinotecan can also undergo CYP3A4-mediated oxidative metabolism to several inactive metabolites, one of which can be hydrolyzed by carboxylesterase to release the active metabolite SN-38. Excretion The disposition of irinotecan has not been fully elucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38, <1%; and SN-38 glucuronide, 3%.

The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m 2) to 50% (300 mg/m 2). Specific Populations Geriatric Patients The pharmacokinetics of irinotecan administered using the weekly schedule was evaluated in a study of 183 patients that was prospectively designed to investigate the effect of age on irinotecan toxicity.

Results from this trial indicate that there are no differences in the pharmacokinetics of irinotecan, SN-38, and SN-38 glucuronide in patients <65 years of age compared with patients ≥65 years of age. In a study of 162 patients that was not prospectively designed to investigate the effect of age, small (less than 18%) but statistically significant differences in dose-normalized irinotecan pharmacokinetic parameters in patients <65 years of age compared to patients ≥65 years of age were observed.

Although dose-normalized AUC 0–24 for SN-38 in patients ≥65 years of age was 11% higher than in patients <65 years of age, this difference was not statistically significant. No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of irinotecan [see Dosage and Administration (2)].

Male and Female Patients The pharmacokinetics of irinotecan do not appear to be influenced by gender. Racial and Ethnic Groups The influence of race on the pharmacokinetics of irinotecan has not been evaluated. Patients with Renal Impairment The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated.

Patients with Hepatic Impairment Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations.

However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Dexamethasone, a moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan. In Vitro Studies Irinotecan and the metabolites SN-38 and aminopentane carboxylic acid (APC) do not inhibit cytochrome P-450 isozymes.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Irinotecan 100 mg/5 mL concentrate Vial₱2,050.00–₱2,900.00Reference ₱2,500.00per vialDPRI procurement range
Irinotecan 40 mg/2 mL concentrate, vial₱533.00per vialDPRI reference price

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Irinotecan (as hydrochloride)
PNF listingInj.: 40 mg/2 mL concentrate, vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 100 mg/5 mL concentrate, vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Camptosar · Pharmacia & Upjohn Company LLC [US FDA-approved label, version 37, May 12, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .